A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to author Dr. James D. Lewis.

Clinical Gastroenterology & Hepatology

Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

An engaging mix of author interviews and expert commentary on the latest articles from Clinical Gastroenterology and Hepatology, hosted by the AGA journals' online editor, John F. Kuemmerle, MD, AGAF.

About

Clinical Gastroenterology & Hepatology